Laurus Labs Q2 Results 2026: FY27 Earnings Preview

Results are scheduled for 29 October

Laurus Labs is scheduled to announce its consolidated financial results for the quarter and half-year ended 30 September 2026 on Thursday, 29 October 2026. The board meeting is due today and will also consider the payment of an interim dividend for FY27. The company has separately scheduled an investor conference call at 5:00 PM IST on the same day to discuss Q2 and H1 FY27 performance. The September quarter is important because it follows a June quarter in which Laurus Labs recorded substantial year-on-year growth in sales, operating profit and net profit.

The company is among more than 140 listed companies expected to report September-quarter earnings on 29 October. Other widely tracked names on the reporting calendar include Coal India, Asian Paints, InterGlobe Aviation, Trent, Suzlon Energy and Ambuja Cements. Laurus Labs' results and any statement on an interim dividend will be monitored by shareholders after the board's decision is disclosed to the exchanges.

What the board meeting will cover

The 13 October board-meeting intimation stated that directors would consider unaudited financial results for the quarter and half-year ended 30 September 2026. The meeting agenda also includes consideration of an interim dividend for FY27. Consideration of a dividend does not mean that a payout has been approved. The final decision, if any, will be known only after the board meeting outcome is filed.

The Q2 FY27 reporting period runs from 1 July 2026 to 30 September 2026. The company is expected to provide revenue, operating-profit and net-profit details for the quarter, along with half-year figures and notes to the accounts. The earnings call, hosted by DAM Capital Advisors, includes management commentary and an interactive question-and-answer session for participants.

June quarter set a higher reference point

Laurus Labs reported consolidated sales of ₹2,026 crore in Q1 FY27, compared with ₹1,570 crore in Q1 FY26 and ₹1,812 crore in the March 2026 quarter. This represented year-on-year sales growth of 29% and quarter-on-quarter growth of 11.85%. EBITDA rose 67% year-on-year to ₹638 crore from ₹382 crore. Net profit increased 124% to ₹362 crore from ₹162 crore.

Earnings per share for the June 2026 quarter stood at ₹6.81, against ₹3.02 in the corresponding quarter a year earlier. The reported June-quarter gross profit was ₹514 crore, up 31.89% sequentially. These figures establish the immediate financial context before the September-quarter announcement, although Q2 results had not been released at the time of the scheduled board meeting.

September 2025 provides the year-on-year base

For a year-on-year comparison, the September 2026 quarter will be measured against Q2 FY26. Laurus Labs reported consolidated sales of ₹1,653 crore and net profit of ₹194 crore in the September 2025 quarter. The comparison is relevant because the June 2026 quarter was materially ahead of both the June 2025 and March 2026 periods.

Quarterly sales have increased from ₹1,570 crore in June 2025 to ₹1,653 crore in September 2025, ₹1,778 crore in December 2025, ₹1,812 crore in March 2026 and ₹2,026 crore in June 2026. Expenses were ₹1,388 crore in June 2026, compared with ₹1,299 crore in March 2026 and ₹1,187 crore in June 2025. The reported figures show the scale of the recent expansion in sales and operating performance, but the September-quarter outcome remains pending.

Key reported financial figures

The company reported annual revenue of ₹6,813 crore in FY26. Its June 2026 result showed revenue of ₹2,026 crore, also presented as ₹20.26 billion in some market-data services. All absolute figures in this report are presented in crore rupees for consistency.

External estimates point to continued attention

Market-data estimates cited ahead of the result place average September-quarter revenue at ₹20.91 billion, equivalent to ₹2,091 crore. The same data source lists an average estimate of ₹83.60 billion, or ₹8,360 crore, for FY27 revenue and ₹96.91 billion, or ₹9,691 crore, for FY28. These are external estimates and are not company guidance.

The available data also noted that consensus EPS estimates had increased by 24%. It cited a forecast for net income to grow 31% in the following year, compared with a 21% growth forecast for the Indian pharmaceuticals industry. Such estimates can change and should be read separately from Laurus Labs' reported financial statements.

Recent earnings have exceeded listed estimates

The market-data record shows actual EPS exceeded listed estimates in four recent quarters. For the quarter ended 30 September 2025, estimated EPS was ₹2.57 while actual EPS was ₹3.61. For the December 2025, March 2026 and June 2026 quarters, actual EPS was ₹4.65, ₹5.17 and ₹6.80, respectively, compared with estimates of ₹3.68, ₹4.98 and ₹4.91.

The June-quarter EPS reported in the company's consolidated results was ₹6.81, while the market-data table rounded it to ₹6.80. The difference reflects rounding rather than a different earnings period. Investors will assess the reported Q2 figure against both the September 2025 base and the recent June-quarter performance.

Why the announcement matters for investors

The Q2 filing will provide the first reported financial view of Laurus Labs for the July-September period. Investors will be able to compare sales, EBITDA, net profit and EPS with the ₹1,653 crore sales and ₹194 crore profit reported in Q2 FY26. They will also assess the half-year result alongside the strong Q1 FY27 figures.

The board's decision on an interim dividend is another event-specific item. Until the board communicates its outcome, there is no confirmed dividend amount or record date. The scheduled earnings call may provide management's explanation of the reported quarterly numbers, although investors should rely on the company's filings and call disclosures for confirmed information.

What to watch after the release

The immediate items to watch are the consolidated Q2 FY27 sales figure, EBITDA, net profit, EPS and the board's decision on the interim dividend. The half-year numbers will show the combined outcome of the June and September quarters. The company is scheduled to hold its conference call at 5:00 PM IST on 29 October, after the results process.

Laurus Labs enters the September-quarter announcement after reporting ₹2,026 crore in Q1 FY27 sales and ₹362 crore in net profit. The formal Q2 FY27 release and subsequent management discussion will determine how the company performed during the July-September 2026 period and whether an interim dividend is declared.